Open Access
Volume 7, Number 1, March 2017
Article Number 1
Number of page(s) 8
Published online 03 March 2017
  1. Jain AK, Blake P, Cordy P, Garg AX. Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012; 23, 533–44. [CrossRef]
  2. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA. Continuous ambulatory peritoneal dialysis and hemodialysis. comparison of patient mortality with adjustment for comorbid conditions. Kidney Int. 1994; 45, 1163–9. [CrossRef] [PubMed]
  3. Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis. what are the important determinants?. Clin Nephrol. 2003; 60, 341–51. [CrossRef] [PubMed]
  4. Mehrotra R M, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011; 171, 110–8. [CrossRef] [PubMed]
  5. Yu X, Yang X. Peritoneal Dialysis in China. Meeting the Challenge of Chronic Kidney Failure. Am J Kidney Dis. 2015; 65, 147–51. [CrossRef] [PubMed]
  6. Heaf JG, Løkkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. NDT 2002; 17, 112–7.
  7. Murphy SW, Foley RN, Barrett BJ, Kent GM, Morgan J, Barré P, et al. Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int. 2000; 57, 1720–6. [CrossRef] [PubMed]
  8. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004; 66, 2389–401. [CrossRef] [PubMed]
  9. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003; 41, 1212–8. [CrossRef] [PubMed]
  10. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Monitoring of inflammation in patients on dialysis. forewarned is forearmed. Nat Rev Nephrol. 2011; 7, 166–76. [CrossRef] [PubMed]
  11. Badiou S, Cristol JP, Jaussent I, Terrier N, Morena M, Maurice F, et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. Clin J Am Soc Nephrol. 2008; 3, 423–30. [CrossRef]
  12. Betjes MG. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013; 9, 255–65. [CrossRef] [PubMed]
  13. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. NDT. 2001; 16, 36–40.
  14. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998; 32, 107–14. [CrossRef] [PubMed]
  15. Pecoits-Filho R, Bárány P, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. NDT. 2002; 17, 1684–8.
  16. Zoccali C, Tripepi G, Mallamaci F. Dissecting inflammation in ESRD. do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?. J Am Soc Nephrol. 2006; 17, S169–S173. [CrossRef]
  17. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003; 290, 353–9. [CrossRef] [PubMed]
  18. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT, et al. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004; 15, 2916–22. [CrossRef]
  19. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Long-term mortality and cardiovascular risk stratification of peritoneal dialysis patients using a combination of inflammation and calcification markers. NDT. 2009; 24, 3826–33.
  20. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG, Ma JZ. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis. 1999; 34, 1065–74. [CrossRef] [PubMed]
  21. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001; 38, 85–90. [CrossRef] [PubMed]
  22. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE. Association between cholesterol level and mortality in dialysis patients. role of inflammation and malnutrition. JAMA. 2004; 291, 451–9. [CrossRef] [PubMed]
  23. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY. Molecular inflammation. underpinnings of aging and age-related diseases. Ageing Res Rev. 2009; 8, 18–30. [CrossRef] [PubMed]
  24. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115, 1111–9. [CrossRef]
  25. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35, 469–476. [CrossRef] [PubMed]
  26. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007; 72, 202–7. [CrossRef] [PubMed]
  27. Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. NDT. 2004; 19, 1154–60.
  28. Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR, et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. NDT. 2008; 23, 566–72.
  29. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2009; 77, 550–6. [CrossRef] [PubMed]
  30. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol. 2004; 15, 2186–94. [CrossRef]
  31. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients. a prospective study. J Am Soc Nephrol. 2003; 14, 159–68. [CrossRef]
  32. Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients. Association with< i> Chlamydia pneumoniae </i> seropositivity. Am J Kidney Dis. 2002; 39, 274–82. [CrossRef] [PubMed]
  33. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD. what is the role of interleukin-6?. Kidney Int. 2002; 61, S103–S108. [CrossRef]
  34. Porazko T, Küzniar J, Kusztal M, Küzniar TJ, Weyde W, Kuriata-Kordek M, Klinger M. IL-18 is involved in vascular injury in endstage renal disease patients. NDT. 2009; 24, 589–96.
  35. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005; 45, 324–33. [CrossRef] [PubMed]
  36. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients. causes and consequences. Am J Kidney Dis. 2003; 42, 864–81. [CrossRef] [PubMed]
  37. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, et al. Endothelial dysfunction in chronic renal failure. roles of lipoprotein oxidation and pro-inflammatory cytokines. NDT. 2001; 16, 1189–97.
  38. Sharma R, Bolger AP, Li W, Davlouros PA, Volk HD, Poole-Wilson PA, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Card. 2003; 92, 188–93. [CrossRef]
  39. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, et al. Inflammatory signals associated with hemodialysis. Kidney Int. 2002; 62, 1408–16. [CrossRef] [PubMed]
  40. Liakopoulos OJ, Dörge H, Schmitto JD, Nagorsnik U, Grabe dünkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. Thorac Cardiovasc Surg. 2006; 54, 250–4. [CrossRef] [PubMed]
  41. Kohut ML, McCann DA, Russell DW, Konopka DN, Cunnick JE, Franke WD, et al. Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of β-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun. 2006; 20, 201–9. [CrossRef]
  42. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE. Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 2002; 87, 252–5. [CrossRef]
  43. Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA. Inhibition of tumour necrosis factor-a and interleukin 6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation. Br J Nutr. 2003; 90, 405–12. [CrossRef] [PubMed]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.